Many phase 3 randomized controlled trials (RCTs) have examined the effect of immunotherapy, including programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade in the adjuvant setting for localized high-risk RCC [5, 6]. This evidence concerns the gene CD274 and renal cell carcinoma.